» Articles » PMID: 9801871

Correlation of SMNt and SMNc Gene Copy Number with Age of Onset and Survival in Spinal Muscular Atrophy

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 1998 Nov 5
PMID 9801871
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Childhood-onset autosomal recessive spinal muscular atrophy (SMA) is associated with absence of the telomeric survival motor neuron gene (SMNt) in most patients, and deletion of the neuronal apoptosis inhibitory protein (NAIP) gene in the majority of severely affected patients. Analysis of SMNt has been complicated by the existence of a centromeric copy, SMNc, which is almost identical to SMNt but which can be distinguished from it by restriction enzyme analysis. In this study 143 SMA patients have been genotyped for the presence or absence of the SMNt, SMNc and NAIP genes, and the data correlated with quantifiable clinical variables. Although a significant correlation was observed between the presence or absence of the NAIP gene and the severity of the clinical phenotype in SMA patients generally, there was no difference in age of onset or survival in type I patients with the NAIP+ or NAIP- genotype. Fluorimetric PCR analysis of SMNc gene dosage in 57 patients homozygous for the absence of the SMNt gene but in whom the NAIP gene was present showed a highly significant correlation between SMNc copy number and SMA subtype, and between SMNc copy number and both age of onset and length of survival. The data provide strong statistical support for the emerging consensus that the clinical phenotype in SMA is directed primarily by the level of functional SMN protein. The lower SMNc copy number in type I patients in whom the NAIP gene is present suggests that the SMNt gene is removed by deletion in the majority of such patients, rather than by gene conversion as is the case in SMA types II and III.

Citing Articles

The impact of three gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review.

Dosi C, Masson R Front Neurol. 2024; 15:1308296.

PMID: 38487326 PMC: 10937544. DOI: 10.3389/fneur.2024.1308296.


Health-Related Quality of Life in Spinal Muscular Atrophy Patients and Their Caregivers-A Prospective, Cross-Sectional, Multi-Center Analysis.

Wohnrade C, Velling A, Mix L, Wurster C, Cordts I, Stolte B Brain Sci. 2023; 13(1).

PMID: 36672091 PMC: 9857112. DOI: 10.3390/brainsci13010110.


Modeling neuromuscular diseases in zebrafish.

Singh J, Patten S Front Mol Neurosci. 2022; 15:1054573.

PMID: 36583079 PMC: 9794147. DOI: 10.3389/fnmol.2022.1054573.


Genomic Variability in the Survival Motor Neuron Genes ( and ): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development.

Butchbach M Int J Mol Sci. 2021; 22(15).

PMID: 34360669 PMC: 8348669. DOI: 10.3390/ijms22157896.


The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment.

Smeriglio P, Langard P, Querin G, Biferi M J Pers Med. 2020; 10(3).

PMID: 32751151 PMC: 7564782. DOI: 10.3390/jpm10030075.